Global pharmaceutical company Eli Lilly (NYSE: LLY) will be reporting results this Thursday before market hours. Here’s what to expect.

Eli Lilly beat analysts’ revenue expectations last quarter, reporting revenues of $19.29 billion, up 42.6% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Is Eli Lilly a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Eli Lilly’s revenue to grow 36.8% year on year, slowing from the 45.2% increase it recorded in the same quarter last year.

Heading into earnings, analysts covering the company have grown increasingly bullish with revenue estimates seeing in majority upward revisions over the last 30 days. Eli Lilly has missed Wall Street’s revenue estimates multiple times over the last two years.

With Eli Lilly being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.8% on average over the last month. Eli Lilly is down 1.5% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.